3 Questions Keeping Juno Therapeutics' Investors Up at Night
Juno Therapeutics (NASDAQ: JUNO) soared ahead of the high-profile American Society of Hematology conference earlier this month, but it's been tough going for investors ever since. The sell-off in its shares is likely being caused by concern over how the company will position its non-Hodgkin lymphoma therapy, JCAR-017, in an increasingly crowded market. Additionally, worry over supply constraints and obstacles to reimbursement are likely at fault, too.
JCAR-017 is a chimeric antigen receptor T-cell therapy (CAR-T) that reengineers a patient's immune system so that it can better find and fight cancer. The therapy involves removing a patient's T-cells, sending them to a facility where they're altered, and infusing them back into the patient. It's a complex and effective approach, but JCAR-017 is far from the only gene therapy that works this way.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com